Brinen & Associates was privileged to represent Odyssey Health, Inc., a medical company focusing on life-enhancing solutions, in the sale of its neurological drug technology pipeline to Oragenics, Inc.
The transaction team included Sarah O’Sullivan, Katie Fitzgerald Madigan, Ifeanyi Okolo and Joshua Brinen.
Under the terms of an Asset Purchase Agreement entered into on October 4, 2023, Oragenics acquired Odyssey’s proprietary assets related to its neurological drug therapy platform under development, including drug candidates for treating mild traumatic brain injury (mTBI, also known as concussion) and Niemann Pick Disease Type C (NPC), along with Odyssey’s proprietary powder formulation and its nasal delivery device.
Brinen & Associates’ Corporate and Transactional Lawyers represent entrepreneurs and the members, partners, C-suite and senior management, and Boards of Directors of small private and public companies in a wide array of domestic and international transactions. They go beyond merely executing clients’ instructions, providing the insight needed to seamlessly navigate the trials and challenges they face while pursuing their business objectives.
About Brinen & Associates
Brinen & Associates specializes in serving the needs of small and micro-cap companies, entrepreneurs, private companies and individuals. The firm’s attorneys effectively serve as outside general counsel for small business clients, addressing the full spectrum of their legal issues, from securities law and taxation to commercial litigation. They strive to provide the same high level of legal expertise expected from a large multinational law firm and are committed to providing professional service with a personal touch.